Clinical trials: Non-Small Cell Carcinoma of Lung
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03654027
- Testing
- Anlotinib Plus Docetaxel, Docetaxel
- Volunteers
- 84 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue near the tumor.
- Trial name
- NCT00551369
- Testing
- SBRT
- Where
- 19 sites in United States
- Volunteers
- 33 people
- Sponsor
- Radiation Therapy Oncology Group
NSCLC With COPD
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
This clinical trial aims to evaluate the efficacy and safety of pembrolizumab in the first-line treatment of advanced NSCLC complicated with COPD and its influence on the course of COPD, so as to provide prospective clinical…
- Trial name
- NCT05578222
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Chest Hospital
Molecular Imaging
EGFR Molecular Classification In Vivo
The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.
- Trial name
- NCT03031522
- Testing
- 18F-IRS
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Harbin Medical University
Non-Small Cell Lung Cancer
ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)
Immunotherapy is a relatively new treatment that uses patients' own immune systems to fight diseases, particularly cancers. Recent studies suggest that the effectiveness of immunotherapy in cancer treatment may depend on the time…
- Trial name
- ITTACA (NCT07661251)
- Volunteers
- 60 people
- Sponsor
- Laura Longshaw
Non-small Cell Lung Cancer, Lung Cancer
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, NSCLC
- Trial name
- NCT01222572
- Testing
- Stereotactic boost, Conventional RT, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer
Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC
This study aimed to investigate the combination of chemotherapy and immunotherapy for patients with metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) who had failed from first line Alectinib.
- Trial name
- CLASSIC5 (NCT04997382)
- Testing
- Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab, Chemotherapy alone or Chemotherapy with or without Bevacizumab
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Hunan Province Tumor Hospital
Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers…
- Conditions
- Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer
- Trial name
- NCT06699979
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Central South University
Non-small Cell Lung Cancer Stage III, KRAS P.G12C
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the…
- Trial name
- MERIT-lung (NCT05398094)
- Testing
- Sotorasib
- Where
- 20 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Fundación GECP
Lung Cancer
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for…
- Trial name
- NCT00006229
- Testing
- carboplatin, paclitaxel, rebimastat
- Where
- 69 sites in United States, Austria and 12 more
- Volunteers
- 774 people
- Sponsor
- NCIC Clinical Trials Group
Triple Negative Breast Cancer, Non Small Cell Lung Cancer
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
- Conditions
- Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
- Trial name
- NCT03808337
- Testing
- Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
- Where
- 12 sites in United States
- Volunteers
- 145 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Carcinoma of Lung, Small Cell Carcinoma of Lung
Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment
Patients with lung cancer often have reduced physical fitness and coexisting health problems, which may limit their ability to tolerate oncological treatment.
- Trial name
- NCT07529145
- Testing
- Cardiopulmonary Exercise Testing (CPET)
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Medical University of Bialystok
Lung Cancer
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in PD-L1 negative, locally advanced or metastatic…
- Trial name
- NCT05690945
- Testing
- QL1706, Tilesizumab
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Non-small Cell Lung Cancer
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00606502
- Testing
- Pralatrexate, Erlotinib, Vitamin B12
- Where
- 47 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Lung Cancer
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004202
- Testing
- carboplatin, chemotherapy, efaproxiral
- Where
- 16 sites in United States, Canada
- Sponsor
- Spectrum Pharmaceuticals, Inc
Pharmacokinetics, Solid Tumor
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults.
- Conditions
- Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
- Trial name
- NCT03396445
- Testing
- Boserolimab, Pembrolizumab, Pemetrexed
- Where
- 18 sites in United States, Chile and 5 more
- Volunteers
- 182 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT04887519
- Testing
- No Intervention
- Where
- Argentina
- Volunteers
- 39 people
- Sponsor
- Takeda
Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
This is an open-label, randomized, multicenter phase II study conducting in 3 medical centers in Asia. Patients will receive erlotinib in combination with bevacizumab or erlotinib alone.
- Trial name
- BRILLIANT (NCT02655536)
- Testing
- Bevacizumab plus erlotinib, Erlotinib
- Where
- Taiwan
- Volunteers
- 109 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.